论文部分内容阅读
在国内首次应用布鲁氏菌酚不溶性组分(PI)治疗慢性布鲁氏菌病84例,临床观察的结果认为 PI 组分能取得与布鲁氏菌苗疗法相同的脱敏效果,近期疗效治愈和基本治愈率可达75%上下,副作用小,临床使用安全,易为患者所接受。
For the first time in China, 84 cases of chronic brucellosis were treated with phenol-insoluble component of brucella (PI). The clinical results showed that the PI component can achieve the same desensitization effect as the Brucella vaccine, and the short-term curative effect Healing and the basic cure rate up and down up and down, side effects, clinical safe, easy for patients to accept.